RU2009148821A - Производные [1,10]фенантролина для лечения нейродегенеративных или гематологических заболеваний - Google Patents
Производные [1,10]фенантролина для лечения нейродегенеративных или гематологических заболеваний Download PDFInfo
- Publication number
- RU2009148821A RU2009148821A RU2009148821/15A RU2009148821A RU2009148821A RU 2009148821 A RU2009148821 A RU 2009148821A RU 2009148821/15 A RU2009148821/15 A RU 2009148821/15A RU 2009148821 A RU2009148821 A RU 2009148821A RU 2009148821 A RU2009148821 A RU 2009148821A
- Authority
- RU
- Russia
- Prior art keywords
- phenanthroline
- alkyl
- compound
- carbaldehyde
- formula
- Prior art date
Links
- 208000014951 hematologic disease Diseases 0.000 title claims abstract 9
- 208000015122 neurodegenerative disease Diseases 0.000 title claims abstract 9
- 230000000626 neurodegenerative effect Effects 0.000 title claims abstract 6
- DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract 41
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract 18
- 239000001257 hydrogen Substances 0.000 claims abstract 18
- 229910052736 halogen Inorganic materials 0.000 claims abstract 16
- 150000002367 halogens Chemical class 0.000 claims abstract 16
- 150000003839 salts Chemical class 0.000 claims abstract 10
- 239000012453 solvate Substances 0.000 claims abstract 10
- 125000001072 heteroaryl group Chemical group 0.000 claims abstract 7
- 208000014644 Brain disease Diseases 0.000 claims abstract 4
- 208000032274 Encephalopathy Diseases 0.000 claims abstract 4
- 201000011240 Frontotemporal dementia Diseases 0.000 claims abstract 4
- 208000027089 Parkinsonian disease Diseases 0.000 claims abstract 4
- 206010034010 Parkinsonism Diseases 0.000 claims abstract 4
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims abstract 4
- 201000006417 multiple sclerosis Diseases 0.000 claims abstract 4
- 208000024827 Alzheimer disease Diseases 0.000 claims abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract 3
- 239000003814 drug Substances 0.000 claims abstract 3
- 230000004770 neurodegeneration Effects 0.000 claims abstract 3
- 230000002265 prevention Effects 0.000 claims abstract 3
- 201000000980 schizophrenia Diseases 0.000 claims abstract 3
- 206010065040 AIDS dementia complex Diseases 0.000 claims abstract 2
- 206010003591 Ataxia Diseases 0.000 claims abstract 2
- 208000011990 Corticobasal Degeneration Diseases 0.000 claims abstract 2
- 206010012289 Dementia Diseases 0.000 claims abstract 2
- 208000002339 Frontotemporal Lobar Degeneration Diseases 0.000 claims abstract 2
- 208000023105 Huntington disease Diseases 0.000 claims abstract 2
- 208000018737 Parkinson disease Diseases 0.000 claims abstract 2
- 208000006011 Stroke Diseases 0.000 claims abstract 2
- 208000034799 Tauopathies Diseases 0.000 claims abstract 2
- 201000004810 Vascular dementia Diseases 0.000 claims abstract 2
- 206010002022 amyloidosis Diseases 0.000 claims abstract 2
- 208000029028 brain injury Diseases 0.000 claims abstract 2
- 201000010099 disease Diseases 0.000 claims abstract 2
- 206010015037 epilepsy Diseases 0.000 claims abstract 2
- 208000028867 ischemia Diseases 0.000 claims abstract 2
- 201000002212 progressive supranuclear palsy Diseases 0.000 claims abstract 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 14
- 238000000034 method Methods 0.000 claims 7
- -1 thiadiazol-2-ylsulfanyl Chemical group 0.000 claims 6
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims 3
- 208000007502 anemia Diseases 0.000 claims 3
- 238000003556 assay Methods 0.000 claims 3
- 239000000460 chlorine Substances 0.000 claims 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 3
- 239000007800 oxidant agent Substances 0.000 claims 3
- 125000003544 oxime group Chemical group 0.000 claims 3
- QCPMMVKHHVZZPC-UHFFFAOYSA-N 2-[[2-(hydroxyiminomethyl)-1,10-phenanthrolin-4-yl]sulfanyl]-N,N-dimethylacetamide Chemical compound C1=CC2=CC=CN=C2C2=C1C(SCC(=O)N(C)C)=CC(C=NO)=N2 QCPMMVKHHVZZPC-UHFFFAOYSA-N 0.000 claims 2
- LDVCBRUWLAPPAI-UHFFFAOYSA-N 4-(2-methoxyethoxy)-1,10-phenanthroline-2-carbaldehyde Chemical compound C1=CC2=CC=CN=C2C2=C1C(OCCOC)=CC(C=O)=N2 LDVCBRUWLAPPAI-UHFFFAOYSA-N 0.000 claims 2
- FOWLOVFYDYBAHG-UHFFFAOYSA-N 4-[2-(diethylamino)ethoxy]-1,10-phenanthroline-2-carbaldehyde Chemical compound C1=CC2=CC=CN=C2C2=C1C(OCCN(CC)CC)=CC(C=O)=N2 FOWLOVFYDYBAHG-UHFFFAOYSA-N 0.000 claims 2
- IVDSDLDJVNSZCW-UHFFFAOYSA-N 4-ethoxy-1,10-phenanthroline-2-carbaldehyde Chemical compound C1=CC2=CC=CN=C2C2=C1C(OCC)=CC(C=O)=N2 IVDSDLDJVNSZCW-UHFFFAOYSA-N 0.000 claims 2
- XACSOWOBGYBJRP-UHFFFAOYSA-N 4-methylsulfanyl-1,10-phenanthroline-2-carbaldehyde Chemical compound C1=CC2=CC=CN=C2C2=C1C(SC)=CC(C=O)=N2 XACSOWOBGYBJRP-UHFFFAOYSA-N 0.000 claims 2
- PBGSOHYXNAMPJZ-UHFFFAOYSA-N 4-propylsulfanyl-1,10-phenanthroline-2-carbaldehyde Chemical compound C1=CC2=CC=CN=C2C2=C1C(SCCC)=CC(C=O)=N2 PBGSOHYXNAMPJZ-UHFFFAOYSA-N 0.000 claims 2
- 208000032467 Aplastic anaemia Diseases 0.000 claims 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 claims 2
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 claims 2
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims 2
- OXODURPTNYMZQT-UHFFFAOYSA-N N-[(4-ethoxy-1,10-phenanthrolin-2-yl)methylidene]hydroxylamine Chemical compound C1=CC2=CC=CN=C2C2=C1C(OCC)=CC(C=NO)=N2 OXODURPTNYMZQT-UHFFFAOYSA-N 0.000 claims 2
- UQNQBPSIKPTMHE-UHFFFAOYSA-N N-[(4-methoxy-1,10-phenanthrolin-2-yl)methylidene]hydroxylamine Chemical compound C1=CC2=CC=CN=C2C2=C1C(OC)=CC(C=NO)=N2 UQNQBPSIKPTMHE-UHFFFAOYSA-N 0.000 claims 2
- QRXQQMRADGXGFK-UHFFFAOYSA-N N-[(4-methylsulfanyl-1,10-phenanthrolin-2-yl)methylidene]hydroxylamine Chemical compound C1=CC2=CC=CN=C2C2=C1C(SC)=CC(C=NO)=N2 QRXQQMRADGXGFK-UHFFFAOYSA-N 0.000 claims 2
- IWOYAXYHVCQRMZ-UHFFFAOYSA-N N-[(4-propylsulfanyl-1,10-phenanthrolin-2-yl)methylidene]hydroxylamine Chemical compound C1=CC2=CC=CN=C2C2=C1C(SCCC)=CC(C=NO)=N2 IWOYAXYHVCQRMZ-UHFFFAOYSA-N 0.000 claims 2
- XFLXQKZCOXFJHN-UHFFFAOYSA-N N-[[4-(1,3,4-thiadiazol-2-ylsulfanyl)-1,10-phenanthrolin-2-yl]methylidene]hydroxylamine Chemical compound C=12C=CC3=CC=CN=C3C2=NC(C=NO)=CC=1SC1=NN=CS1 XFLXQKZCOXFJHN-UHFFFAOYSA-N 0.000 claims 2
- XHWSCKBRJMHQNN-UHFFFAOYSA-N N-[[4-(1,3-thiazol-2-ylsulfanyl)-1,10-phenanthrolin-2-yl]methylidene]hydroxylamine Chemical compound C=12C=CC3=CC=CN=C3C2=NC(C=NO)=CC=1SC1=NC=CS1 XHWSCKBRJMHQNN-UHFFFAOYSA-N 0.000 claims 2
- BKLFSKLZVSOTSA-UHFFFAOYSA-N N-[[4-(2,2,2-trifluoroethylsulfanyl)-1,10-phenanthrolin-2-yl]methylidene]hydroxylamine Chemical compound C1=CN=C2C3=NC(C=NO)=CC(SCC(F)(F)F)=C3C=CC2=C1 BKLFSKLZVSOTSA-UHFFFAOYSA-N 0.000 claims 2
- NLDRUGJKXMUBNB-UHFFFAOYSA-N N-[[4-(2-aminoethoxy)-1,10-phenanthrolin-2-yl]methylidene]hydroxylamine Chemical compound C1=CC2=CC=CN=C2C2=C1C(OCCN)=CC(C=NO)=N2 NLDRUGJKXMUBNB-UHFFFAOYSA-N 0.000 claims 2
- IVVVOHHUKULMHM-UHFFFAOYSA-N N-[[4-(2-methoxyethoxy)-1,10-phenanthrolin-2-yl]methylidene]hydroxylamine Chemical compound C1=CC2=CC=CN=C2C2=C1C(OCCOC)=CC(C=NO)=N2 IVVVOHHUKULMHM-UHFFFAOYSA-N 0.000 claims 2
- BIRFTRJZOJQTAM-UHFFFAOYSA-N N-[[4-(2-methoxyethylsulfanyl)-1,10-phenanthrolin-2-yl]methylidene]hydroxylamine Chemical compound C1=CC2=CC=CN=C2C2=C1C(SCCOC)=CC(C=NO)=N2 BIRFTRJZOJQTAM-UHFFFAOYSA-N 0.000 claims 2
- MEUXNGHRPZBVGN-UHFFFAOYSA-N N-[[4-[2-(diethylamino)ethoxy]-1,10-phenanthrolin-2-yl]methylidene]hydroxylamine Chemical compound C1=CC2=CC=CN=C2C2=C1C(OCCN(CC)CC)=CC(C=NO)=N2 MEUXNGHRPZBVGN-UHFFFAOYSA-N 0.000 claims 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims 2
- 208000002903 Thalassemia Diseases 0.000 claims 2
- 125000003172 aldehyde group Chemical group 0.000 claims 2
- 230000030833 cell death Effects 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 229910052742 iron Inorganic materials 0.000 claims 2
- KSCOTUFBSRGWRW-UHFFFAOYSA-N methyl 2-[[2-(hydroxyiminomethyl)-1,10-phenanthrolin-4-yl]sulfanyl]acetate Chemical compound C1=CC2=CC=CN=C2C2=C1C(SCC(=O)OC)=CC(C=NO)=N2 KSCOTUFBSRGWRW-UHFFFAOYSA-N 0.000 claims 2
- 230000001590 oxidative effect Effects 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 230000004224 protection Effects 0.000 claims 2
- 159000000000 sodium salts Chemical class 0.000 claims 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 1
- XFHAFZMDCPIBFV-UHFFFAOYSA-N 2-[[2-(hydroxyiminomethyl)-1,10-phenanthrolin-4-yl]sulfanyl]acetic acid Chemical compound C1=CN=C2C3=NC(C=NO)=CC(SCC(O)=O)=C3C=CC2=C1 XFHAFZMDCPIBFV-UHFFFAOYSA-N 0.000 claims 1
- PMUNNIFYZKSPMJ-UHFFFAOYSA-N 4-chloro-1,10-phenanthroline-2-carbaldehyde Chemical compound C1=CC2=CC=CN=C2C2=C1C(Cl)=CC(C=O)=N2 PMUNNIFYZKSPMJ-UHFFFAOYSA-N 0.000 claims 1
- 230000007466 Aβ secretion Effects 0.000 claims 1
- 208000020925 Bipolar disease Diseases 0.000 claims 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 claims 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 1
- 208000019022 Mood disease Diseases 0.000 claims 1
- KMXWIVKHINXODS-UHFFFAOYSA-N N-[(4-chloro-1,10-phenanthrolin-2-yl)methylidene]hydroxylamine Chemical compound C1=CN=C2C3=NC(C=NO)=CC(Cl)=C3C=CC2=C1 KMXWIVKHINXODS-UHFFFAOYSA-N 0.000 claims 1
- AEXLFFUDBSFTKU-UHFFFAOYSA-N N-[(4-propan-2-ylsulfanyl-1,10-phenanthrolin-2-yl)methylidene]hydroxylamine Chemical compound C1=CC2=CC=CN=C2C2=C1C(SC(C)C)=CC(C=NO)=N2 AEXLFFUDBSFTKU-UHFFFAOYSA-N 0.000 claims 1
- NELLQHDJKZEOMJ-UHFFFAOYSA-N N-[[4-[(5-methyl-1,3-thiazol-2-yl)sulfanyl]-1,10-phenanthrolin-2-yl]methylidene]hydroxylamine Chemical compound S1C(C)=CN=C1SC1=CC(C=NO)=NC2=C1C=CC1=CC=CN=C21 NELLQHDJKZEOMJ-UHFFFAOYSA-N 0.000 claims 1
- 208000030886 Traumatic Brain injury Diseases 0.000 claims 1
- 150000004703 alkoxides Chemical class 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 150000001412 amines Chemical class 0.000 claims 1
- 238000004166 bioassay Methods 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 230000008499 blood brain barrier function Effects 0.000 claims 1
- 210000001218 blood-brain barrier Anatomy 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 230000009920 chelation Effects 0.000 claims 1
- 239000003153 chemical reaction reagent Substances 0.000 claims 1
- 229910052801 chlorine Inorganic materials 0.000 claims 1
- 125000001309 chloro group Chemical group Cl* 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 125000001664 diethylamino group Chemical group [H]C([H])([H])C([H])([H])N(*)C([H])([H])C([H])([H])[H] 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 210000003743 erythrocyte Anatomy 0.000 claims 1
- 230000005986 heart dysfunction Effects 0.000 claims 1
- 208000018706 hematopoietic system disease Diseases 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 230000003993 interaction Effects 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 230000004112 neuroprotection Effects 0.000 claims 1
- DIVDFFZHCJEHGG-UHFFFAOYSA-N oxidopamine Chemical compound NCCC1=CC(O)=C(O)C=C1O DIVDFFZHCJEHGG-UHFFFAOYSA-N 0.000 claims 1
- 238000002732 pharmacokinetic assay Methods 0.000 claims 1
- 230000001737 promoting effect Effects 0.000 claims 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 238000011084 recovery Methods 0.000 claims 1
- 230000035939 shock Effects 0.000 claims 1
- 208000007056 sickle cell anemia Diseases 0.000 claims 1
- 239000011734 sodium Substances 0.000 claims 1
- 229910052708 sodium Inorganic materials 0.000 claims 1
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 claims 1
- HMTFGKVHBABVOV-UHFFFAOYSA-M sodium;propanethioate Chemical compound [Na+].CCC([O-])=S HMTFGKVHBABVOV-UHFFFAOYSA-M 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 150000003512 tertiary amines Chemical class 0.000 claims 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims 1
- 150000007944 thiolates Chemical class 0.000 claims 1
- 231100000419 toxicity Toxicity 0.000 claims 1
- 230000001988 toxicity Effects 0.000 claims 1
- 230000009529 traumatic brain injury Effects 0.000 claims 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 7
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 4
- 125000003118 aryl group Chemical group 0.000 abstract 2
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07380167.2 | 2007-06-11 | ||
| EP07380167A EP2002863A1 (en) | 2007-06-11 | 2007-06-11 | [1,10]-phenanthroline derivatives for the treatment of neurodegenerative or haematological diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2009148821A true RU2009148821A (ru) | 2011-07-20 |
Family
ID=38596362
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2009148821/15A RU2009148821A (ru) | 2007-06-11 | 2008-06-11 | Производные [1,10]фенантролина для лечения нейродегенеративных или гематологических заболеваний |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US8592446B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP2002863A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2010529167A (cg-RX-API-DMAC7.html) |
| CN (1) | CN101801461A (cg-RX-API-DMAC7.html) |
| AR (1) | AR066956A1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2008263897A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2690455A1 (cg-RX-API-DMAC7.html) |
| CL (1) | CL2008001719A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2009013482A (cg-RX-API-DMAC7.html) |
| RU (1) | RU2009148821A (cg-RX-API-DMAC7.html) |
| TW (1) | TW200914016A (cg-RX-API-DMAC7.html) |
| UY (1) | UY31143A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2008152068A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6000272B2 (ja) | 2010-12-01 | 2016-09-28 | 中国石油化工股▲ふん▼有限公司 | 窒素のオルソ位にアシル基が置換した窒素含有複素環式化合物およびそのアミナール鉄（ｉｉ）錯体の製造方法 |
| CN102532201B (zh) * | 2010-12-01 | 2014-11-05 | 中国石油化工股份有限公司 | 甲酰基取代的1,10-菲咯啉配合物的制备及由此制备的配合物作为催化剂的应用 |
| CN102558241B (zh) * | 2010-12-01 | 2014-11-26 | 中国石油化工股份有限公司 | 丙酰基取代的1,10-菲咯啉配合物的制备及由此制备的配合物作为催化剂的应用 |
| CN106083713B (zh) * | 2016-07-15 | 2019-07-26 | 浙江工业大学 | 一种喹(喔)啉-2-甲醛类化合物的化学合成方法 |
| WO2021176428A1 (en) * | 2020-03-06 | 2021-09-10 | Jawaharlal Nehru Centre For Advanced Scientific Research | Phenanthroline, carbazole and flavylium based cyanines and compositions and methods of making and using the same |
| CA3232921A1 (en) * | 2021-09-28 | 2023-04-06 | Zevra Denmark A/S | Oximes and their use in treatment of gba-related diseases |
| CN117983303B (zh) * | 2022-11-01 | 2026-04-07 | 万华化学集团股份有限公司 | 一种金属配合物及其配体，催化剂组合物及香茅醇的制备方法 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL76345B1 (cg-RX-API-DMAC7.html) * | 1971-02-13 | 1975-06-30 |
-
2007
- 2007-06-11 EP EP07380167A patent/EP2002863A1/en not_active Withdrawn
-
2008
- 2008-06-11 CL CL2008001719A patent/CL2008001719A1/es unknown
- 2008-06-11 CN CN200880102953A patent/CN101801461A/zh active Pending
- 2008-06-11 AU AU2008263897A patent/AU2008263897A1/en not_active Abandoned
- 2008-06-11 EP EP08760868A patent/EP2170464A2/en not_active Withdrawn
- 2008-06-11 UY UY31143A patent/UY31143A1/es not_active Application Discontinuation
- 2008-06-11 TW TW097121744A patent/TW200914016A/zh unknown
- 2008-06-11 AR ARP080102479A patent/AR066956A1/es unknown
- 2008-06-11 RU RU2009148821/15A patent/RU2009148821A/ru not_active Application Discontinuation
- 2008-06-11 CA CA2690455A patent/CA2690455A1/en not_active Abandoned
- 2008-06-11 MX MX2009013482A patent/MX2009013482A/es not_active Application Discontinuation
- 2008-06-11 WO PCT/EP2008/057319 patent/WO2008152068A2/en not_active Ceased
- 2008-06-11 JP JP2010511627A patent/JP2010529167A/ja active Pending
- 2008-06-11 US US12/664,130 patent/US8592446B2/en active Active - Reinstated
-
2013
- 2013-09-15 US US14/027,225 patent/US20140011835A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CN101801461A (zh) | 2010-08-11 |
| JP2010529167A (ja) | 2010-08-26 |
| WO2008152068A2 (en) | 2008-12-18 |
| CL2008001719A1 (es) | 2009-01-02 |
| MX2009013482A (es) | 2010-01-27 |
| US20140011835A1 (en) | 2014-01-09 |
| UY31143A1 (es) | 2009-01-30 |
| US20100240692A1 (en) | 2010-09-23 |
| CA2690455A1 (en) | 2008-12-18 |
| AU2008263897A1 (en) | 2008-12-18 |
| AR066956A1 (es) | 2009-09-23 |
| WO2008152068A3 (en) | 2009-05-07 |
| EP2170464A2 (en) | 2010-04-07 |
| EP2002863A1 (en) | 2008-12-17 |
| TW200914016A (en) | 2009-04-01 |
| US8592446B2 (en) | 2013-11-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6117430B2 (ja) | 選択的ヒストン脱アセチル化酵素抑制剤としての新規化合物およびこれを含む薬剤学的組成物 | |
| JP2021176846A (ja) | スルファモイル−アリールアミド及びｂ型肝炎の治療のための薬剤としてのその使用 | |
| WO2023029380A1 (zh) | 作为glp1r激动剂的新型芳醚取代杂环类化合物 | |
| JP2009509986A5 (cg-RX-API-DMAC7.html) | ||
| CN109790135B (zh) | 用于治疗或预防与痛风或高尿酸血症相关的症状的化合物、组合物和方法 | |
| JP2011500562A5 (cg-RX-API-DMAC7.html) | ||
| JP2010528089A5 (cg-RX-API-DMAC7.html) | ||
| FR2876692A1 (fr) | Derives de 2-amido-4-phenylthiazole, leur preparation et leur application en therapeutique | |
| CN109152752A (zh) | 一种金刚烷胺类化合物及其制备方法和用途 | |
| JP2010529167A5 (cg-RX-API-DMAC7.html) | ||
| EP3844155A1 (en) | Compounds useful as chaperone-mediated autophagy modulators | |
| EP4313951A1 (en) | 1,3-substituted cyclobutyl derivatives and uses thereof | |
| JPWO2001036402A1 (ja) | 新規な２−（ｎ−シアノイミノ）チアゾリジン−４−オン誘導体 | |
| JP2023529295A (ja) | 縮合環誘導体及びその薬学的用途 | |
| WO2006089225A1 (en) | 5- [4- (4- (2 -amino- 2 -methoxycarbonylethyl) phenoxy) benzilidene] thiazolidin-2 , 4-dion e derivatives and related compounds for reducing glucose, cholesterol and triglyceride levels in plasma | |
| WO2019105234A1 (zh) | 芳香族化合物及其药物组合物和用途 | |
| TW202146381A (zh) | 可用作RORγ調節劑的聯芳基類化合物 | |
| EP4003955A1 (en) | Inhibitors of human atgl | |
| AU2014245879A1 (en) | Phenyl derivative | |
| JP2022518526A (ja) | カルバメート誘導体およびその使用 | |
| CN101573321A (zh) | 二羟基蒽醌羧酸盐及其治疗用途 | |
| JP2022046644A (ja) | マイコバクテリア感染症の処置のためのヘテロアリールトリフルオロボレート化合物 | |
| CN114790186A (zh) | 作为ep4拮抗剂的稠环化合物及其制备方法和用途 | |
| WO2001007031A1 (en) | Benzene derivatives and immunopotentiating compositions or drug-sensitivity restoring agents containing the same | |
| RU2008134509A (ru) | Новые соединения и их применение |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA94 | Acknowledgement of application withdrawn (non-payment of fees) |
Effective date: 20130902 |